1.000000
0.000000
0.000000
0.000000
1.000000
0.000000
0.000000
0.000000
1.000000
0.00000
0.00000
0.00000
Briese, L.
Willbold, D.
http://mmcif.pdb.org/dictionaries/ascii/mmcif_pdbx.dic
C3 H7 N O2
89.093
y
ALANINE
L-peptide linking
C6 H15 N4 O2 1
175.209
y
ARGININE
L-peptide linking
C4 H8 N2 O3
132.118
y
ASPARAGINE
L-peptide linking
C4 H7 N O4
133.103
y
ASPARTIC ACID
L-peptide linking
C5 H10 N2 O3
146.144
y
GLUTAMINE
L-peptide linking
C5 H9 N O4
147.129
y
GLUTAMIC ACID
L-peptide linking
C2 H5 N O2
75.067
y
GLYCINE
peptide linking
C6 H10 N3 O2 1
156.162
y
HISTIDINE
L-peptide linking
C6 H13 N O2
131.173
y
ISOLEUCINE
L-peptide linking
C6 H13 N O2
131.173
y
LEUCINE
L-peptide linking
C6 H15 N2 O2 1
147.195
y
LYSINE
L-peptide linking
C9 H11 N O2
165.189
y
PHENYLALANINE
L-peptide linking
C5 H9 N O2
115.130
y
PROLINE
L-peptide linking
C3 H7 N O3
105.093
y
SERINE
L-peptide linking
C4 H9 N O3
119.119
y
THREONINE
L-peptide linking
C11 H12 N2 O2
204.225
y
TRYPTOPHAN
L-peptide linking
C9 H11 N O3
181.189
y
TYROSINE
L-peptide linking
C5 H11 N O2
117.146
y
VALINE
L-peptide linking
UK
Bmc Struct.Biol.
1472-6807
3
3
3
10.1186/1472-6807-3-3
12734017
Structure determination of human Lck unique and SH3 domains by nuclear magnetic resonance spectroscopy.
2003
10.2210/pdb1kik/pdb
pdb_00001kik
1.000000
0.000000
0.000000
0.000000
1.000000
0.000000
0.000000
0.000000
1.000000
0.00000
0.00000
0.00000
1
SINGLE WAVELENGTH
M
1
1.0
6411.063
PROTO-ONCOGENE TYROSINE-PROTEIN KINASE LCK
2.7.1.112
SH3 DOMAIN (RESIDUES 64-120)
1
man
polymer
P56-LCK, LSK, T cell-specific protein-tyrosine kinase
no
no
NLVIALHSYEPSHDGDLGFEKGEQLRILEQSGEWWKAQSLTTGQEGFIPFNFVAKAN
NLVIALHSYEPSHDGDLGFEKGEQLRILEQSGEWWKAQSLTTGQEGFIPFNFVAKAN
A
polypeptide(L)
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
human
Homo
Escherichia
Escherichia coli
sample
9606
Homo sapiens
511693
Escherichia coli BL21
BL21
plasmid
pGEX-6P-2
database_2
pdbx_struct_assembly
pdbx_struct_oper_list
repository
Initial release
Version format compliance
Version format compliance
Database references
Derived calculations
1
0
2001-12-12
1
1
2008-04-27
1
2
2011-07-13
1
3
2022-02-23
_database_2.pdbx_DOI
_database_2.pdbx_database_accession
Sh3-Sh2 Domain Fragment Of Human P56-Lck Tyrosine Kinase Complexed With The 10 Residue Synthetic Phosphotyrosyl Peptide Tegqpyqpqpa Complex (Kinase/Peptide)
Sh3 Domain Of Human Lck Tyrosine Kinase
Sh2 (Src Homology-2) Domain Of Human P56-Lck Tyrosine Kinase Complexed With The 11 Residue Phosphotyrosyl Peptide Epqpyeeipiyl Complex (Kinase/Peptide)
Structural Analysis Of The Lymphocyte-Specific Kinase Lck In Complex With Non-Selective and Src Family Selective Kinase Inhibitors
RCSB
Y
RCSB
2001-12-03
REL
REL
structures with the lowest energy
150
25
3D_13C-separated_NOESY
3D_15N-separated_NOESY
HNHA
20
6.5
1
atm
298
K
20
6.5
1
atm
298
K
simulated annealing
1
lowest energy
1,6mM Lck unique and SH3 domains, U-15N,13C; 20 mM sodium acetate
90% H2O/10% D2O
1mM Lck unique and SH3 domains, U-15N; 20 mM sodium acetate
90% H2O/10% D2O
collection
VNMR
5.3b
processing
PROSA
2.9
data analysis
XEASY
1.3.13
structure solution
ARIA
1.0
refinement
CNS
1.0
750
Varian
INOVA
600
Varian
INOVA
ASN
64
n
1
ASN
64
A
LEU
65
n
2
LEU
65
A
VAL
66
n
3
VAL
66
A
ILE
67
n
4
ILE
67
A
ALA
68
n
5
ALA
68
A
LEU
69
n
6
LEU
69
A
HIS
70
n
7
HIS
70
A
SER
71
n
8
SER
71
A
TYR
72
n
9
TYR
72
A
GLU
73
n
10
GLU
73
A
PRO
74
n
11
PRO
74
A
SER
75
n
12
SER
75
A
HIS
76
n
13
HIS
76
A
ASP
77
n
14
ASP
77
A
GLY
78
n
15
GLY
78
A
ASP
79
n
16
ASP
79
A
LEU
80
n
17
LEU
80
A
GLY
81
n
18
GLY
81
A
PHE
82
n
19
PHE
82
A
GLU
83
n
20
GLU
83
A
LYS
84
n
21
LYS
84
A
GLY
85
n
22
GLY
85
A
GLU
86
n
23
GLU
86
A
GLN
87
n
24
GLN
87
A
LEU
88
n
25
LEU
88
A
ARG
89
n
26
ARG
89
A
ILE
90
n
27
ILE
90
A
LEU
91
n
28
LEU
91
A
GLU
92
n
29
GLU
92
A
GLN
93
n
30
GLN
93
A
SER
94
n
31
SER
94
A
GLY
95
n
32
GLY
95
A
GLU
96
n
33
GLU
96
A
TRP
97
n
34
TRP
97
A
TRP
98
n
35
TRP
98
A
LYS
99
n
36
LYS
99
A
ALA
100
n
37
ALA
100
A
GLN
101
n
38
GLN
101
A
SER
102
n
39
SER
102
A
LEU
103
n
40
LEU
103
A
THR
104
n
41
THR
104
A
THR
105
n
42
THR
105
A
GLY
106
n
43
GLY
106
A
GLN
107
n
44
GLN
107
A
GLU
108
n
45
GLU
108
A
GLY
109
n
46
GLY
109
A
PHE
110
n
47
PHE
110
A
ILE
111
n
48
ILE
111
A
PRO
112
n
49
PRO
112
A
PHE
113
n
50
PHE
113
A
ASN
114
n
51
ASN
114
A
PHE
115
n
52
PHE
115
A
VAL
116
n
53
VAL
116
A
ALA
117
n
54
ALA
117
A
LYS
118
n
55
LYS
118
A
ALA
119
n
56
ALA
119
A
ASN
120
n
57
ASN
120
A
author_defined_assembly
1
monomeric
1.0000000000
0.0000000000
0.0000000000
0.0000000000
1.0000000000
0.0000000000
0.0000000000
0.0000000000
1.0000000000
1_555
x,y,z
identity operation
0.0000000000
0.0000000000
0.0000000000
A
O
ILE
111
A
O
ILE
48
A
N
TRP
98
A
N
TRP
35
A
O
GLN
101
A
O
GLN
38
A
N
ARG
89
A
N
ARG
26
A
O
LEU
88
A
O
LEU
25
A
N
VAL
66
A
N
VAL
3
A
N
ILE
67
A
N
ILE
4
A
O
ALA
117
A
O
ALA
54
1
A
A
H
O
LEU
PHE
80
110
1.56
2
A
A
H
O
LEU
PHE
80
110
1.60
6
A
A
H
O
LEU
PHE
80
110
1.57
7
A
A
H
O
LEU
PHE
80
110
1.60
8
A
A
H
O
LEU
PHE
80
110
1.56
11
A
A
H
O
LEU
PHE
80
110
1.58
14
A
A
H
O
LEU
PHE
80
110
1.58
17
A
A
H
O
LEU
PHE
80
110
1.56
18
A
A
H
O
LEU
PHE
80
110
1.59
20
A
A
H
O
LEU
PHE
80
110
1.55
23
A
A
H
O
LEU
PHE
80
110
1.57
24
A
A
H
O
LEU
PHE
80
110
1.58
25
A
A
H
O
LEU
PHE
80
110
1.57
1
A
PRO
74
-37.21
126.22
1
A
SER
102
-49.35
167.90
1
A
PRO
112
-52.64
108.34
1
A
ASN
114
-98.97
30.36
1
A
LYS
118
-39.67
139.25
1
A
ALA
119
-69.35
54.44
2
A
PRO
74
-37.65
120.45
2
A
SER
102
-49.98
167.81
2
A
PRO
112
-53.62
109.77
2
A
ASN
114
-99.12
30.87
2
A
LYS
118
-39.59
139.09
2
A
ALA
119
-69.01
53.98
3
A
PRO
74
-36.34
132.43
3
A
SER
75
-130.53
-43.65
3
A
GLN
93
-140.25
36.70
3
A
LYS
118
-39.53
138.91
3
A
ALA
119
-69.25
54.38
4
A
PRO
74
-37.22
129.36
4
A
SER
102
-49.08
167.17
4
A
LYS
118
-39.59
139.03
4
A
ALA
119
-69.19
54.51
5
A
PRO
74
-37.14
133.58
5
A
SER
102
-49.51
166.66
5
A
LYS
118
-39.36
137.98
5
A
ALA
119
-69.08
54.51
6
A
PRO
74
-36.83
127.56
6
A
SER
102
-49.42
167.64
6
A
LYS
118
-39.46
139.48
6
A
ALA
119
-69.84
53.82
7
A
PRO
74
-36.27
131.69
7
A
SER
75
-130.10
-43.22
7
A
SER
102
-49.41
168.40
7
A
LYS
118
-39.58
138.94
7
A
ALA
119
-69.61
54.28
8
A
PRO
74
-37.04
122.14
8
A
SER
102
-49.57
167.43
8
A
LYS
118
-39.65
140.43
8
A
ALA
119
-69.80
50.89
9
A
PRO
74
-37.72
120.02
9
A
SER
102
-49.86
167.75
9
A
ASN
114
-98.81
31.63
9
A
LYS
118
-39.40
138.58
9
A
ALA
119
-69.56
54.41
10
A
PRO
74
-36.92
124.46
10
A
SER
102
-49.69
167.70
10
A
LYS
118
-39.38
138.51
10
A
ALA
119
-69.32
54.77
11
A
PRO
74
-36.77
123.93
11
A
SER
102
-49.25
167.71
11
A
PRO
112
-51.68
109.95
11
A
ASN
114
-98.69
30.37
11
A
LYS
118
-39.47
139.48
11
A
ALA
119
-69.68
53.95
12
A
PRO
74
-35.95
131.38
12
A
SER
75
-130.01
-43.48
12
A
SER
102
-49.70
167.37
12
A
LYS
118
-39.52
138.76
12
A
ALA
119
-69.67
53.78
13
A
PRO
74
-37.40
123.19
13
A
SER
102
-49.75
166.96
13
A
LYS
118
-39.42
139.32
13
A
ALA
119
-69.94
54.00
14
A
PRO
74
-36.73
126.81
14
A
GLU
96
-49.63
-19.95
14
A
SER
102
-49.73
168.01
14
A
ASN
114
-98.99
30.83
14
A
LYS
118
-39.38
139.63
15
A
PRO
74
-37.90
123.71
15
A
SER
102
-49.82
166.54
15
A
LYS
118
-39.53
139.40
15
A
ALA
119
-69.59
53.47
16
A
PRO
74
-35.03
126.73
16
A
LYS
118
-39.47
138.24
16
A
ALA
119
-68.80
54.89
17
A
PRO
74
-36.48
128.22
17
A
SER
102
-49.21
167.58
17
A
LYS
118
-39.48
140.79
18
A
PRO
74
-37.12
125.86
18
A
SER
102
-49.54
167.96
18
A
ASN
114
-99.84
31.70
18
A
LYS
118
-39.50
139.27
18
A
ALA
119
-69.48
54.19
19
A
PRO
74
-39.41
112.93
19
A
SER
102
-49.77
166.34
19
A
LYS
118
-39.33
139.17
19
A
ALA
119
-69.93
54.54
20
A
PRO
74
-36.61
125.63
20
A
SER
102
-49.73
167.43
20
A
LYS
118
-39.60
138.21
20
A
ALA
119
-68.89
54.69
21
A
PRO
74
-35.91
128.72
21
A
GLU
96
-49.84
-19.99
21
A
SER
102
-49.91
167.95
21
A
LYS
118
-39.57
140.72
22
A
PRO
74
-37.08
127.28
22
A
SER
102
-49.52
167.72
22
A
LYS
118
-39.39
140.15
23
A
PRO
74
-36.40
132.93
23
A
SER
75
-130.28
-42.48
23
A
GLN
93
-140.63
37.51
23
A
LYS
118
-39.49
138.84
23
A
ALA
119
-69.47
54.31
24
A
PRO
74
-37.09
128.71
24
A
SER
102
-49.25
168.00
24
A
ASN
114
-99.08
30.81
24
A
LYS
118
-39.56
139.33
24
A
ALA
119
-69.42
54.56
25
A
PRO
74
-36.66
129.87
25
A
GLN
93
-141.47
37.39
25
A
SER
102
-49.77
167.81
25
A
LYS
118
-39.55
140.47
SH3 Domain of Lymphocyte Specific Kinase (LCK)
1
N
N
TRANSFERASE
SH3 DOMAIN, TYROSINE KINASE, SIGNAL TRANSDUCTION, LCK, TRANSFERASE
LCK_HUMAN
UNP
1
63
P06239
NLVIALHSYEPSHDGDLGFEKGEQLRILEQSGEWWKAQSLTTGQEGFIPFNFVAKAN
63
119
1KIK
64
120
P06239
A
1
1
57
5
anti-parallel
anti-parallel
anti-parallel
anti-parallel
A
GLU
108
A
GLU
45
A
PRO
112
A
PRO
49
A
TRP
97
A
TRP
34
A
SER
102
A
SER
39
A
GLN
87
A
GLN
24
A
GLU
92
A
GLU
29
A
LEU
65
A
LEU
2
A
ALA
68
A
ALA
5
A
VAL
116
A
VAL
53
A
LYS
118
A
LYS
55